Is Sanofi India a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sanofi India Ltd is a good quality company .

Is Sanofi India undervalued or overvalued?

The key valuation ratios of Sanofi India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Sanofi India share price return in the past 10 years?

Sanofi India Ltd share price has appreciated 7% annually (CAGR) over the past ten years.

Is Sanofi India a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Sanofi India Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Sanofi India Ltd - Stock Valuation and Financial Performance

Name: Sanofi India
Brand: Sanofi India

BSE: 500674 | NSE: SANOFI | Pharmaceuticals & Drugs | Small Cap

Place order

Sanofi India Share Price

₹6,278.45 -292.05 -4.44%
as on 25-Apr'25 16:59

10 Year X-Ray of Sanofi India:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	TTM
ROCE % ⓘ	31%	27.5%	26.4%	28.8%	25.8%	29.8%	58%	49.5%	46.3%	46.2%	-
Value Creation Index ⓘ	1.3	1.0	1.0	1.1	0.9	1.2	3.3	2.7	2.4	2.4	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	2,193	2,367	2,464	2,771	3,071	2,902	2,957	2,770	1,996	2,013	2,013
Sales YoY Gr.	-	7.9%	4.1%	12.5%	10.8%	-5.5%	1.9%	-6.3%	-27.9%	0.9%	-
Adj EPS ⓘ	114.3	131.3	139.9	163.5	197.9	220.9	259.2	229.4	153.1	146.9	136.2
YoY Gr.	-	14.9%	6.6%	16.8%	21.1%	11.6%	17.4%	-11.5%	-33.3%	-4.1%	-
BVPS (₹) ⓘ	707.3	810.7	869.9	950.2	1,043.5	897.8	941.5	527.7	411.8	344	343.5
Adj Net Profit ⓘ	263	302	322	377	456	509	597	528	352	338	314
Cash Flow from Ops. ⓘ	213	322	435	374	412	611	559	399	231	462	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-1%	-8.1%	-12%	0.9%
Adj EPS ⓘ	2.8%	-5.8%	-17.3%	-4.1%
BVPSⓘ	-7.7%	-19.9%	-28.5%	-16.5%
Share Price	7%	-3.7%	-3.8%	-24.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	TTM
Return on Equity % ⓘ	16.9	17.2	16.5	17.7	19.6	22.3	27.5	30.2	30.8	36.1	39.6
Op. Profit Mgn % ⓘ	21	22.6	21.9	22.6	21.7	24.7	25.8	25.4	24.5	24.4	25.6
Net Profit Mgn % ⓘ	12	12.8	13.1	13.6	14.9	17.5	20.2	19.1	17.7	16.8	15.6
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	149	156	287	379	386	419	436	446	656	709	92
Cash Conv. Cycle ⓘ	39	50	31	20	18	13	2	-3	48	41	29

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 39.60%

Sales growth has been subdued in last 3 years -12.02%

Net Profit has been subdued in last 3 years -17.26%

Sales growth is not so good in last 4 quarters at 1.50%

Latest Financials - Sanofi India Ltd.

	Standalone	Consolidated
TTM EPS (₹)	136.2	179.5
TTM Sales (₹ Cr.)	2,013	2,013
BVPS (₹.) ⓘ	343.5	343.5
Reserves (₹ Cr.) ⓘ	768	768
P/BV ⓘ	18.28	18.28
PE ⓘ	46.09	34.99

From the Market
52 Week Low / High (₹)	4145.90 / 10526.05
All Time Low / High (₹)	235.05 / 10526.05
Market Cap (₹ Cr.)	14,460
Equity (₹ Cr.)	23
Face Value (₹)	10
Industry PE ⓘ	39.3

Quarterly Results

Standalone Basis

Consolidated Basis

	Mar'24	YoY Gr. Rt. %	Jun'24	YoY Gr. Rt. %	Sep'24	YoY Gr. Rt. %	Dec'24	YoY Gr. Rt. %
Sales (₹ Cr.)ⓘ	1,306	79.1	904	11.5	918	4.9	975	-1.1
Adj EPS (₹) ⓘ	18.3	48.3	13	-3.2	6.1	-13.7	7.1	-9.3
Op. Profit Mgn % ⓘ	47.99	-1109 bps	58.73	-200 bps	56.39	-143 bps	56.69	73 bps
Net Profit Mgn % ⓘ	29.77	-580 bps	34.71	-103 bps	31.66	-306 bps	34.84	-4 bps

Management X-Ray of Sanofi India:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Sanofi India

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

No data found!

Key Ratios of Sanofi India

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Peer Comparison

Company Name	CMP(₹)	Change ₹(%)	Market Cap	Net Sales (₹ Cr.)	Latest EPS (₹)	Net Profit Margin %	Latest P/E	Latest P/BV
Alembic Pharma	875.5	-6 (-0.7%)	Small Cap	6,229	30.8	9.6	28.7	3.5
Laurus Labs	625.4	-21.8 (-3.4%)	Small Cap	5,041	6.6	3.1	97.4	8.3
Piramal Pharma	216	-3.9 (-1.8%)	Small Cap	4,390	5.2	8.4	42.4	4.1
Ajanta Pharma	2,677.2	-108.9 (-3.9%)	Small Cap	4,209	71.9	19	38.8	8.9
Gland Pharma	1,451.4	-14.2 (-1%)	Small Cap	4,167	68.1	24.8	21.5	2.6
Natco Pharma	889.7	-14 (-1.6%)	Small Cap	3,999	104.1	34.5	8.7	2.2
Granules India	452.2	-23.6 (-5%)	Small Cap	3,755	13.3	11.7	35.8	3.5
Emcure Pharma	1,027.8	-47.9 (-4.5%)	Small Cap	3,498	8.5	4.4	126.7	7.1
JB Chem & Pharma	1,576.1	-33.8 (-2.1%)	Small Cap	3,299	40.4	16.1	39.9	7.6
Wockhardt	1,396.4	-70.7 (-4.8%)	Small Cap	2,798	-11.8	-15.3	-	5.4

Shows rows:

Prev 1 2 3 4 5 Next

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24
Sales	2,193	2,367	2,464	2,771	3,071	2,902	2,957	2,770	1,996	2,013
Operating Expenses ⓘ	1,734	1,832	1,926	2,148	2,405	2,189	2,194	2,067	1,509	1,523
Manufacturing Costs	217	121	120	144	142	114	88	84	34	45
Material Costs	912	1,065	1,004	1,146	1,347	1,254	1,307	1,190	954	979
Employee Cost	333	355	369	407	450	461	434	406	281	240
Other Costs ⓘ	272	290	434	451	466	361	366	387	241	258
Operating Profit ⓘ	459	535	537	623	665	713	762	703	487	490
Operating Profit Margin (%)	20.9%	22.6%	21.8%	22.5%	21.7%	24.6%	25.8%	25.4%	24.4%	24.4%
Other Income ⓘ	51	66	81	90	94	90	75	73	62	17
Interest ⓘ	0	2	1	1	0	2	2	2	2	2
Depreciation ⓘ	113	119	102	103	100	82	67	42	37	37
Exceptional Items ⓘ	84	0	0	0	-59	-42	489	132	18	-38
Profit Before Tax ⓘ	481	480	515	610	600	677	1,258	864	529	431
Tax ⓘ	159	176	189	229	186	200	313	244	164	118
Profit After Tax	322	304	326	381	414	478	944	621	365	314
PAT Margin (%)	14.7%	12.9%	13.2%	13.7%	13.5%	16.5%	31.9%	22.4%	18.3%	15.6%
Adjusted EPS (₹)	139.8	132.3	141.7	165.5	180.1	207.7	410.6	269.8	158.5	136.4
Dividend Payout Ratio (%)	47%	51%	50%	51%	194%	176%	119%	211%	105%	86%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24
Equity and Liabilities
Shareholders Fund	1,627	1,865	2,001	2,186	2,400	2,065	2,166	1,214	947	791
Share Capital ⓘ	23	23	23	23	23	23	23	23	23	23
Reserves ⓘ	1,604	1,842	1,978	2,163	2,377	2,042	2,143	1,191	924	768
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0	0	0	0	0	0	0	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Trade Payables	226	231	327	344	369	318	377	356	292	406
Others Liabilities ⓘ	552	446	1,996	2,240	2,471	2,710	3,013	3,258	3,465	3,482
Total Liabilities ⓘ	2,405	2,541	4,324	4,769	5,240	5,093	5,555	4,828	4,703	4,679
Fixed Assets
Gross Block	1,454	936	989	1,053	817	852	546	531	544	568
Accumulated Depreciation	577	119	220	321	318	388	212	225	229	255
Net Fixed Assetsⓘ	877	817	769	733	499	464	334	306	315	313
CWIP ⓘ	22	34	30	21	17	10	13	24	16	18
Investmentsⓘ	0	0	0	0	0	0	0	0	2	0
Inventories	479	493	416	483	470	368	392	408	664	500
Trade Receivables	144	145	195	158	224	148	143	129	132	230
Cash Equivalents	572	561	730	832	1,130	1,209	1,550	1,017	405	295
Others Assetsⓘ	310	492	2,184	2,542	2,901	2,895	3,123	2,945	3,170	3,324
Total Assets ⓘ	2,405	2,541	4,324	4,769	5,240	5,093	5,555	4,828	4,703	4,679

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24
Cash Flow From Operating Activity ⓘ	213	322	435	374	412	611	559	399	231	462
PBT ⓘ	397	480	515	610	600	677	1,258	864	846	563
Adjustment ⓘ	66	61	39	36	78	65	-482	-159	-25	25
Changes in Working Capital ⓘ	-112	-1	80	-28	-38	62	68	-46	-349	-29
Tax Paid ⓘ	-138	-218	-198	-244	-228	-193	-285	-261	-241	-97
Cash Flow From Investing Activity ⓘ	36	-155	-79	-73	66	276	631	651	36	-19
Capex	-29	-69	-57	-57	-75	-41	-13	13	-10	-36
Net Investments	-1	0	0	0	0	0	0	0	0	0
Others ⓘ	65	-86	-22	-16	141	317	643	638	46	17
Cash Flow From Financing Activityⓘ	-147	-180	-188	-197	-183	-810	-849	-1,583	-878	-392
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	-2	-2	-2	-2	-2
Dividend Paid ⓘ	-147	-150	-157	-164	-152	-804	-841	-1,573	-868	-385
Others ⓘ	0	-31	-32	-34	-31	-5	-7	-8	-8	-6
Net Cash Flow ⓘ	102	-13	168	104	295	78	341	-533	-612	50

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24
Ratios
ROE (%)	20.68	17.43	16.87	18.18	18.07	21.39	44.65	36.73	33.75	36.09
ROCE (%)	30.96	27.51	26.38	28.76	25.75	29.77	57.98	49.47	46.28	46.15
Asset Turnover Ratio	0.97	0.98	0.73	0.63	0.64	0.56	0.56	0.56	0.44	0.44
PAT to CFO Conversion(x)	0.66	1.06	1.33	0.98	1	1.28	0.59	0.64	0.63	1.47
Working Capital Days
Receivable Days	21	22	25	22	22	23	18	17	23	32
Inventory Days	78	73	67	57	54	53	47	50	94	103
Payable Days	111	78	101	107	97	100	97	112	124	130

Sanofi India Ltd Stock News

View All News

Sanofi India Ltd FAQs

What is the share price of Sanofi India?

Company share prices are keep on changing according to the market conditions. The closing price of Sanofi India on 25-Apr-2025 16:59 is ₹6,278.5.

What is the market cap of Sanofi India?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 25-Apr-2025 16:59 the market cap of Sanofi India stood at ₹14,459.7.

What is the P/E ratio of Sanofi India?

The latest P/E ratio of Sanofi India as of 25-Apr-2025 16:59 is 46.09.

What is the P/B ratio of Sanofi India?

The latest P/B ratio of Sanofi India as of 25-Apr-2025 16:59 is 18.28.

What is the 52-week high and low of Sanofi India?

The 52-week high of Sanofi India is ₹10,526.1 and the 52-week low is ₹4,145.9.

What is the TTM revenue of Sanofi India?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sanofi India is ₹2,013 ( Cr.) .

About Sanofi India Ltd

Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Sanofi, one of the world's leading healthcare companies, and its 100% subsidiary - Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange and the National Stock Exchange. The company has two manufacturing sites in Ankleshwar and Goa. Sanofi India also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams and ointments. These products are manufactured in accordance with the same quality standards as those prevalent at its own manufacturing sites for domestic consumption and for export to Russia, the Ukraine and other CIS countries.

Business area of the company

The company is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

Products

Pharmaceutical products (Adenocor, Aldurazyme, AllStar, Amaryl, Apidra, Arava, Aubagio, Augeoz, Brodactam, Cardace, Caspercid, Cerezyme, Cetapin, Clexane, Cordarone, Daonil, Depakote, Fabrazyme, Fasturtec, Fludara, Frisium, Insuman, Jevtana, Lantus, Lasilactone, Lasix, Lyxumia, Metosan, M-Nem, Myoril, Myozyme, Plavix, Primacor, Renvela Sachets, Soframycin, Solian, Stilnoct, Synvisc, Targocid, Taxotere, Telsite, Thymoglobuline, Thyrogen, Toujeo, Trental, Valparin, Vinlep, Zemiglo).

Vaccines (Adacel, Avaxim, FluQuadri, Hexaxim, Imovax Polio, Menactra, Pentaxim, Shan5, Shanchol, ShanIPV, ShanTT, Shanvac-B, Stamaril, Vaxigrip)

Consumer Healthcare products (Allegra, Allegra, Allegra M, Aminofit Forte, Amino-fit, Avil, Baralgan NU, Berrycran, Buscogast, Cetgel, Collaflex, Combiflam Plus, Combiflam Suspension, Combiflam IcyHotTM, Combiflam IcyHotTM spray, CoQ 300, DePURA by Sanofi, Dulcoflex Natural, DulcoSoft Sachet, E-Cod Plus, E-Cod W, Enlarge Forte, Enterogermina, Estoven XT, Festal N, FreeFlex Forte, Icegel, Lactacyd, Macraberin M, Mega FreeFlex, Multivite Gold, Multivite Woman, Multivite CD,
Multivite-FM Omega, Novalgin NU, Phospholip TF, Primosa, Radiance H, Seacod Active, Selace Forte,
Triomega)

Milestones

2013: Sanofi India launches Combiflam Plus.
2013: Sanofi ties up with IDF, PHFI to fight against diabetes among children in India.
2013: Sanofi India inks pact with Suzlon Energy for renewable energy.
2014: Sanofi India - Diabetic Teen from Pune achieves unique feat.
2014: Sanofi partners with Emcure Pharmaceuticals for marketing and distribution of its oncology portfolio in India.
2015: Sanofi delivers 4 lakh Shan5 vaccine doses to Gwalior and Jabalpur to support the immunization of children from five pediatric diseases.
2016: Sanofi India collaborates with National Institute of Pharmaceutical Education and Research (NIPER) Kolkata, to promote academic excellence and research.
2018: Sanofi receives positive CHMP opinion for dengue vaccine.
2018: Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure.
2019: Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu in Flu Care.
2020: Sanofi Completes Acquisition of Synthorx, Inc.
2020: Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine.
2020: Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas.